巨人症や下垂体腫瘍の有病率の増加が市場の成長を促進しています。例えば、2021年5月に発表された記事「韓国における巨人症の記述疫学と生存分析」によると、年間平均発生率は100万人あたり4.2件、同期間の有病率は100万人あたり32.1件でした。また、2021年7月に発表された「巨人症の全球疫学：系統的レビューとメタアナリシス」というタイトルの記事によると、系統的レビューに含まれた32の研究のうち、メタアナリシスに含まれた22の研究からの結果では、巨人症のプールされた有病率は10万人あたり5.9件でした。さらに、2020年にオーストラリア下垂体財団の更新によると、現在715人から3,500人のオーストラリア人が巨人症を患っており、これは約7,300人から35,700人のオーストラリア人に対して1人の巨人症の患者がいることを示しています。したがって、これらの統計は、巨人症の治療に対する需要が近い将来に増加し、市場の成長に寄与することを示しています。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場力学

  • 4.1 市場概要

  • 4.2 市場の促進要因

    • 4.2.1 増加する先端巨大症と下垂体腫瘍の有病率・発生率

    • 4.2.2 世界的に高まる先端巨大症への認識

    • 4.2.3 先端巨大症の新薬開発における技術的な進歩

  • 4.3 市場の抑制要因

    • 4.3.1 治療に伴う合併症について

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模別、金額、百万米ドル）

  • 5.1 製品タイプ別

    • 5.1.1 ソマトスタチン類似体

    • 5.1.2 成長ホルモン受容体拮抗薬(GHRA)

    • 5.1.3 ドーパミン作動薬

    • 5.1.4 その他の製品タイプ

  • 5.2 地域別

    • 5.2.1 北米

      • 5.2.1.1 米国
      • 5.2.1.2 カナダ
      • 5.2.1.3 メキシコ

    • 5.2.2 ヨーロッパ

      • 5.2.2.1 ドイツ
      • 5.2.2.2 英国
      • 5.2.2.3 フランス
      • 5.2.2.4 イタリア
      • 5.2.2.5 スペイン
      • 5.2.2.6 その他ヨーロッパ

    • 5.2.3 アジア太平洋

      • 5.2.3.1 中国
      • 5.2.3.2 日本
      • 5.2.3.3 インド
      • 5.2.3.4 オーストラリア
      • 5.2.3.5 韓国
      • 5.2.3.6 その他アジア太平洋

    • 5.2.4 中東・アフリカ

      • 5.2.4.1 GCC地域
      • 5.2.4.2 南アフリカ
      • 5.2.4.3 その他中東・アフリカ

    • 5.2.5 南米

      • 5.2.5.1 ブラジル
      • 5.2.5.2 アルゼンチン
      • 5.2.5.3 その他南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 Pfizer Inc

    • 6.1.2 Novartis AG

    • 6.1.3 Validus Pharmaceuticals LLC

    • 6.1.4 Ipsen

    • 6.1.5 Chiasma, Inc

    • 6.1.6 Crinetics Pharmaceuticals

    • 6.1.7 Ionis Pharmaceuticals Inc

    • 6.1.8 Midatech Pharma Plc

    • 6.1.9 ADVANZ PHARMA

    • 6.1.10 Amolyt Pharma

• 7 市場機会と今後の動向

The Acromegaly Treatment Market is expected to register a CAGR of 7.4% during the forecast period, 2022-2027.

The COVID-19 pandemic has significantly impacted acromegaly treatment. For instance, as per a November 2020 published article titled, "Growth hormone deficiency, acromegaly, and COVID-19: Transitioning from media reports to knowledge and a growth hormone hypothesis", having acromegaly does theoretically increase the risk of COVID-19 because of its associated comorbidities such as cardiovascular complications, diabetes mellitus, obstructive sleep apnea syndrome, chest wall deformity, upper airway obstruction, and intrathoracic collapse. Additionally, per a March 2021 published article titled, "Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting", patients with acromegaly have several characteristics that could potentially worsen their outcome if they develop COVID-19. Thus, such studies indicate that patients with COVID-19 disease are at high risk. Hence, the demand for acromegaly treatment is expected to increase in the near future.

Further, the significant factors contributing to the market's growth are the increasing prevalence and incidence of acromegaly and pituitary tumors; growing awareness regarding the disease worldwide; and technological advancements in developing new drugs for acromegaly.

The increasing prevalence of acromegaly and pituitary tumors is boosting the market growth. For instance, as per a May 2021 published article, "Descriptive Epidemiology and Survival Analysis of Acromegaly in Korea," the average annual incidence was 4.2 per million per year, and the prevalence was 32.1 cases per million during this period. Also, as per a July 2021 published article titled, "Global epidemiology of acromegaly: a systematic review and meta-analysis," the results revealed that out of a total of 32 studies included in the systematic review and 22 of them included in the meta-analysis, the pooled prevalence of acromegaly was 5.9 per 100,000 people. Moreover, as per a 2020 update by the Australian Pituitary Foundation, between 715 and 3,500 Australians currently live with acromegaly, representing around one person with acromegaly every 7,300 to 35,700 Australians. Thus, the statistics indicate that the demand for acromegaly treatment will increase shortly, thereby contributing to market growth.

However, complications associated with the treatment are a significant factor restraining the market's growth.

Key Market Trends

Somatostatin Analogs Segment is Expected to Hold a Major Market Share in the Acromegaly Treatment Market

The somatostatin analogs segment is anticipated to hold a significant market share by product type. This can be attributed to the wide availability of drugs and cost-efficiency. Somatostatin analogs have been prescribed as first-line treatment options as they are highly effective. Some examples of available marketed drugs are somavert, Signifor LAR, Sandostatin LAR, Somatuline Depot, and Parlodel.

Also, the increasing number of product approvals is driving the market's growth. For instance, in June 2020, Chiasma, Inc., a commercial-stage biopharmaceutical company, reported that the United States Food and Drug Administration (FDA) approved MYCAPSSA(octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first, and only oral somatostatin analog (SSA) approved by the FDA and the first product approved by the FDA utilizing Chiasma’s Transient Permeability Enhancer (TPE) technology. Also, in June 2021, the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly.

Thus, the market is expected to witness significant growth over the forecast period due to the abovementioned factors.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global acromegaly treatment market due to the high demand for innovative products. According to the National Institutes of Health (NIH) and Endocrine Society, in 13 studies of acromegaly prevalence, researchers estimate that roughly 24,000 individuals live with acromegaly in the United States, of which an estimated 8,000 people are treated chronically with somatostatin analog injections.

Furthermore, the presence of top pharma and biotech companies involved in developing products for acromegaly treatment is contributing to the market's growth. For instance, in June 2021, Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1. This trial will be one of two planned Phase 3 studies assessing the safety and efficacy of once-daily oral paltusotine in acromegaly patients that together will evaluate paltusotine in a broad cross-section of acromegaly patients.

Thus, the market is expected to witness significant growth over the forecast period due to the above developments.

Competitive Landscape

The Acromegaly treatment market is consolidated and competitive and consists of a few significant players. Some prominent players operating in the acromegaly market are Pfizer Inc., Novartis AG, Validus Pharmaceuticals LLC, and Ipsen. Some companies involved in developing products for acromegaly are Chiasma, Inc., Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Inc., and Midatech Pharma Plc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Increasing Prevalence and Incidence of Acromegaly and Pituitary Tumors

    • 4.2.2 Growing Awareness Regarding Acromegaly Disease Worldwide

    • 4.2.3 Technological Advancements in Development of New Drugs for Acromegaly

  • 4.3 Market Restraints

    • 4.3.1 Complications Associated with the Treatment

  • 4.4 Porter's Five Force Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type

    • 5.1.1 Somatostatin Analogs

    • 5.1.2 Growth Hormone Receptor Antagonist (GHRA)

    • 5.1.3 Dopamine Agonists

    • 5.1.4 Other Product Types

  • 5.2 Geography

    • 5.2.1 North America

      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico

    • 5.2.2 Europe

      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe

    • 5.2.3 Asia-Pacific

      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific

    • 5.2.4 Middle-East and Africa

      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa

    • 5.2.5 South America

      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Pfizer Inc

    • 6.1.2 Novartis AG

    • 6.1.3 Validus Pharmaceuticals LLC

    • 6.1.4 Ipsen

    • 6.1.5 Chiasma, Inc

    • 6.1.6 Crinetics Pharmaceuticals

    • 6.1.7 Ionis Pharmaceuticals Inc

    • 6.1.8 Midatech Pharma Plc

    • 6.1.9 ADVANZ PHARMA

    • 6.1.10 Amolyt Pharma

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS